Efficacy and Safety of Antibody Drug Conjugates in Previously Treated Hormone Receptor Positive HER2 Negative (or Low) Metastatic Breast Cancer–A Systematic Review and Meta-Analysis
T-DXd demonstrated better efficacy in pretreated HR+/HER2-low metastatic breast cancer (MBC), especially in earlier lines. SG showed significant OS benefit primarily in later lines. Dato-DXd showed no OS benefit but had the most favorable safety profile.
Authors
- Fazal Hassan (ORCID: https://orcid.org/0000-0003-0226-7705)
- Dingde Ye
- Yijin Huang (ORCID: https://orcid.org/0000-0002-1482-185X)
- Melissa Hart
- Qingxiang Xu
Institutions
- Anhui Medical University (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- University of Missouri (US)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1097/coc.0000000000001259
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00